comprehensive -WSS

comprehensive

author：comprehensive 2025-10-03 00:03:54 - browse：5

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Stanford president's case begs question: Who takes blame?

entertainment

WSS

Wildfire smoke exposes gaps in outdoor worker protections

Tori Bowie and the unacceptable rates of Black maternal death

Tesla recalling nearly 16,000 of its 2021

Medicare proposal to cover medical devices draws a mixed reaction

Driven by the pandemic, applicants flood public health schools

Walensky prepares to leave CDC — and Congress — behind

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hollywood unions extend contract negotiations for actors

Hospitals struggle to profit from CAR

Continuity nursing helped my family in our darkest PICU moments

Why Congress must ban federal programs from using QALYs

Moonlake's readout produced a cash windfall. Risks remain

Judge rejects Trump's request to move Stormy Daniels hush

Apple is now the first public company to be valued at $3 trillion

Why Congress must ban federal programs from using QALYs

The high cost of giving birth even with insurance

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug repurposing or repositioning? The language matters

Hospitals struggle to profit from CAR

Hospitals struggle to profit from CAR

As demand for Covid shots wanes, Moderna seeks its next success

Alkermes shareholders re

focus

entertainment

hotspot

hotspot